82 related articles for article (PubMed ID: 11314029)
1. Cellular and viral Fos proteins are degraded by different proteolytic systems.
Acquaviva C; Salvat C; Brockly F; Bossis G; Ferrara P; Piechaczyk M; Jariel-Encontre I
Oncogene; 2001 Feb; 20(8):942-50. PubMed ID: 11314029
[TBL] [Abstract][Full Text] [Related]
2. The structural determinants responsible for c-Fos protein proteasomal degradation differ according to the conditions of expression.
Ferrara P; Andermarcher E; Bossis G; Acquaviva C; Brockly F; Jariel-Encontre I; Piechaczyk M
Oncogene; 2003 Mar; 22(10):1461-74. PubMed ID: 12629509
[TBL] [Abstract][Full Text] [Related]
3. Evasion from proteasomal degradation by mutated Fos proteins expressed from FBJ-MSV and FBR-MSV osteosarcomatogenic retroviruses.
Acquaviva C; Bossis G; Ferrara P; Brockly F; Jariel-Encontre I; Piechaczyk M
Biochem Pharmacol; 2002 Sep; 64(5-6):957-61. PubMed ID: 12213592
[TBL] [Abstract][Full Text] [Related]
4. Multiple degradation pathways for Fos family proteins.
Acquaviva C; Bossis G; Ferrara P; Brockly F; Jariel-Encontre I; Piechaczyk M
Ann N Y Acad Sci; 2002 Nov; 973():426-34. PubMed ID: 12485905
[TBL] [Abstract][Full Text] [Related]
5. Degradation of cellular and viral Fos proteins.
Acquaviva C; Ferrara P; Bossis G; Brockly F; Salvat C; Jariel-Encontre I; Piechaczyk M
Biochimie; 2001; 83(3-4):357-62. PubMed ID: 11295497
[TBL] [Abstract][Full Text] [Related]
6. Decreased susceptibility to calpains of v-FosFBR but not of v-FosFBJ or v-JunASV17 retroviral proteins compared with their cellular counterparts.
Steff AM; Carillo S; Pariat M; Piechaczyk M
Biochem J; 1997 May; 323 ( Pt 3)(Pt 3):685-92. PubMed ID: 9169601
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitin-independent- versus ubiquitin-dependent proteasomal degradation of the c-Fos and Fra-1 transcription factors: is there a unique answer?
Basbous J; Jariel-Encontre I; Gomard T; Bossis G; Piechaczyk M
Biochimie; 2008 Feb; 90(2):296-305. PubMed ID: 17825471
[TBL] [Abstract][Full Text] [Related]
8. Identification of a C-terminal tripeptide motif involved in the control of rapid proteasomal degradation of c-Fos proto-oncoprotein during the G(0)-to-S phase transition.
Acquaviva C; Brockly F; Ferrara P; Bossis G; Salvat C; Jariel-Encontre I; Piechaczyk M
Oncogene; 2001 Nov; 20(51):7563-72. PubMed ID: 11709728
[TBL] [Abstract][Full Text] [Related]
9. Ubiquitin-independent proteasomal degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilizer.
Basbous J; Chalbos D; Hipskind R; Jariel-Encontre I; Piechaczyk M
Mol Cell Biol; 2007 Jun; 27(11):3936-50. PubMed ID: 17371847
[TBL] [Abstract][Full Text] [Related]
10. c-fos expression induces bone tumors in transgenic mice.
Rüther U; Komitowski D; Schubert FR; Wagner EF
Oncogene; 1989 Jul; 4(7):861-5. PubMed ID: 2547184
[TBL] [Abstract][Full Text] [Related]
11. c-Fos degradation by the ubiquitin-proteasome proteolytic pathway in osteoclast progenitors.
Ito Y; Inoue D; Kido S; Matsumoto T
Bone; 2005 Dec; 37(6):842-9. PubMed ID: 16172035
[TBL] [Abstract][Full Text] [Related]
12. v-FBR-fos oncogene fails to rescue mammalian cells from growth arrest but affects the responses of human fibroblasts to heparin.
Kolettas E; Evangelou A; Gonos ES
Anticancer Res; 2001; 21(1A):435-44. PubMed ID: 11299775
[TBL] [Abstract][Full Text] [Related]
13. Proto-oncogene fos: an inducible multifaceted gene.
Mitchell RL; Hanks SK; Verma IM
Symp Fundam Cancer Res; 1986; 39():99-113. PubMed ID: 2827284
[TBL] [Abstract][Full Text] [Related]
14. Protein stabilization: a common consequence of mutations in independently derived v-Myc alleles.
Gavine PR; Neil JC; Crouch DH
Oncogene; 1999 Dec; 18(52):7552-8. PubMed ID: 10602514
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of myristylation on transrepression by FBR (Gag-Fos) protein.
Kamata N; Holt JT
Mol Cell Biol; 1992 Feb; 12(2):876-82. PubMed ID: 1310154
[TBL] [Abstract][Full Text] [Related]
16. N-terminal destruction signals lead to rapid degradation of the major histocompatibility complex class II transactivator CIITA.
Schnappauf F; Hake SB; Camacho Carvajal MM; Bontron S; Lisowska-Grospierre B; Steimle V
Eur J Immunol; 2003 Aug; 33(8):2337-47. PubMed ID: 12884309
[TBL] [Abstract][Full Text] [Related]
17. Identification of a small region of the v-fos gene product that is sufficient for transforming potential and growth-stimulating activity.
Yoshida T; Shindo Y; Ohta K; Iba H
Oncogene Res; 1989; 5(2):79-89. PubMed ID: 2514403
[TBL] [Abstract][Full Text] [Related]
18. The V protein of human parainfluenza virus 2 antagonizes type I interferon responses by destabilizing signal transducer and activator of transcription 2.
Parisien JP; Lau JF; Rodriguez JJ; Sullivan BM; Moscona A; Parks GD; Lamb RA; Horvath CM
Virology; 2001 May; 283(2):230-9. PubMed ID: 11336548
[TBL] [Abstract][Full Text] [Related]
19. Complex mechanisms for c-fos and c-jun degradation.
Jariel-Encontre I; Salvat C; Steff AM; Pariat M; Acquaviva C; Furstoss O; Piechaczyk M
Mol Biol Rep; 1997 Mar; 24(1-2):51-6. PubMed ID: 9228281
[TBL] [Abstract][Full Text] [Related]
20. Presenilin modulates Pen-2 levels posttranslationally by protecting it from proteasomal degradation.
Crystal AS; Morais VA; Fortna RR; Carlin D; Pierson TC; Wilson CA; Lee VM; Doms RW
Biochemistry; 2004 Mar; 43(12):3555-63. PubMed ID: 15035625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
